Imlifidase denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for imlifidase are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Imlifidase as Experimental or Investigational

Aetna, like other large insurers, maintains a clinical policy bulletin that classifies certain therapies as experimental or investigational when it determines the evidence base does not yet meet its standard for established clinical benefit. Imlifidase has received regulatory approval (it holds a European Medicines Agency marketing authorization and FDA has reviewed the product in the context of kidney transplantation), but coverage policies can lag regulatory status, and insurers sometimes apply an "experimental" label even to conditionally or conditionally-approved agents when they consider the overall evidence insufficient by their internal standard.

An experimental denial is one of the harder denial types to overturn, but it is fully appealable — and independent external reviewers are not bound by Aetna's internal policy classification.

## Your Federal Appeal Rights

• Internal appeal: Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal review. Submit your appeal with clinical evidence within the deadline stated on the denial letter.
• External review: This denial type is particularly well-suited to external review. An accredited IRO will apply recognized medical standards — not Aetna's internal policy — and must determine whether the service is covered under the terms of the plan and applicable law. File within approximately four months of the final internal adverse decision.
• Expedited option: Transplant-context urgency typically qualifies for expedited review — decisions within 72 hours or fewer.

## What to Gather Before You File

1. Aetna's current clinical policy bulletin on imlifidase: Obtain the specific bulletin number and version from Aetna's website or your denial letter. Your appeal must address each basis for the experimental classification. 2. FDA and regulatory status documentation: Confirm and document the current FDA regulatory status of imlifidase for the specific use requested. A product's regulatory approval status is a primary argument against an experimental classification. 3. Transplant team expert letter: The prescribing transplant physician should explain the evidence base for imlifidase in this clinical context, citing the applicable specialty society guidance (e.g., guidance from AST, ASTS, or similar transplant-focused organizations) without inventing statistics — just referencing the organization and that a guideline exists. 4. Evidence of institutional use: If the patient's transplant center uses imlifidase as part of a published or recognized institutional protocol, documentation of that protocol supports the argument that use is consistent with accepted practice. 5. Patient-specific necessity: Chart documentation of the clinical factors that make this patient a candidate for imlifidase-assisted transplantation.

## Criteria-Mapping Structure

| Aetna Experimental Classification Basis | Your Counter-Evidence | Source | |---|---|---| | Lacks regulatory approval for this use | [Current regulatory status] | FDA documentation | | Lacks established clinical benefit | [Specialist society recognition] | Transplant team letter + guideline org reference | | Not consistent with accepted practice | [Institutional protocol / center experience] | Hospital protocol document | | Alternative options exist | [Addressed by transplant team] | Clinical letter |

External reviewers applying objective medical standards have reversed experimental denials in transplant contexts when regulatory status and specialty society support are clearly documented.